Terms: = Germ cell tumor AND MYCN, N-myc, 4613, ENSG00000134323, NMYC, MODED, ODED AND Prognosis
892 results:
1. A multi-omics approach for biomarker discovery in neuroblastoma: a network-based framework.
Hussein R; Abou-Shanab AM; Badr E
NPJ Syst Biol Appl; 2024 May; 10(1):52. PubMed ID: 38760476
[TBL] [Abstract] [Full Text] [Related]
2. KAP1 stabilizes mycn mRNA and promotes neuroblastoma tumorigenicity by protecting the RNA m
Yang Y; Zhang Y; Chen G; Sun B; Luo F; Gao Y; Feng H; Li Y
J Exp Clin Cancer Res; 2024 May; 43(1):141. PubMed ID: 38745192
[TBL] [Abstract] [Full Text] [Related]
3. Multifactoral immune modulation potentiates durable remission in multiple models of aggressive malignancy.
Halpert MM; Burns BA; Rosario SR; Withers HG; Trivedi AJ; Hofferek CJ; Gephart BD; Wang H; Vazquez-Perez J; Amanya SB; Hyslop ST; Yang J; Kemnade JO; Sandulache VC; Konduri V; Decker WK
FASEB J; 2024 May; 38(10):e23644. PubMed ID: 38738472
[TBL] [Abstract] [Full Text] [Related]
4. LOXL1-AS1 contributes to metastasis in sonic-hedgehog medulloblastoma by promoting cancer stem-like phenotypes.
Do AD; Wu KS; Chu SS; Giang LH; Lin YL; Chang CC; Wong TT; Hsieh CL; Sung SY
J Exp Clin Cancer Res; 2024 Apr; 43(1):130. PubMed ID: 38689348
[TBL] [Abstract] [Full Text] [Related]
5. Analysis of the relationship between mycn gene and serum NSE and urinary VMA levels and neuroblastoma pathological features and prognosis.
Zhang H; He X; Miao Q; Li L; Song J; Jiang X
Cell Mol Biol (Noisy-le-grand); 2024 Apr; 70(4):134-139. PubMed ID: 38678619
[TBL] [Abstract] [Full Text] [Related]
6. SESN1 functions as a new tumor suppressor gene via Toll-like receptor signaling pathway in neuroblastoma.
Hua Z; Chen B; Gong B; Lin M; Ma Y; Li Z
CNS Neurosci Ther; 2024 Mar; 30(3):e14664. PubMed ID: 38516781
[TBL] [Abstract] [Full Text] [Related]
7. Targeting of neuroblastoma cells through Kynurenine-AHR pathway inhibition.
Dos Santos IL; Mitchell M; Nogueira PAS; Lafita-Navarro MC; Perez-Castro L; Eriom J; Kilgore JA; Williams NS; Guo L; Xu L; Conacci-Sorrell M
FEBS J; 2024 May; 291(10):2172-2190. PubMed ID: 38431776
[TBL] [Abstract] [Full Text] [Related]
8. Genetic and epigenetic features of neuroendocrine prostate cancer and their emerging applications.
Zhang X; Barnett E; Smith J; Wilkinson E; Subramaniam RM; Zarrabi A; Rodger EJ; Chatterjee A
Int Rev Cell Mol Biol; 2024; 383():41-66. PubMed ID: 38359970
[TBL] [Abstract] [Full Text] [Related]
9. MTHFD1 regulates the NADPH redox homeostasis in mycn-amplified neuroblastoma.
Guan J; Li M; Wang Y; Zhang Y; Que Y; Lu S; Wang J; Zhu J; Huang J; Zhen Z; Sun F; Song M; Zhang Y
Cell Death Dis; 2024 Feb; 15(2):124. PubMed ID: 38336749
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic and predictive biomarkers in central nervous system tumours: the molecular state of play.
Satgunaseelan L; Sy J; Shivalingam B; Sim HW; Alexander KL; Buckland ME
Pathology; 2024 Mar; 56(2):158-169. PubMed ID: 38233331
[TBL] [Abstract] [Full Text] [Related]
11. Prognostic and predictive biomarkers in paediatric solid tumours.
Glembocki AI; Somers GR
Pathology; 2024 Mar; 56(2):283-296. PubMed ID: 38216399
[TBL] [Abstract] [Full Text] [Related]
12. PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1/PD-L1 blockade in neuroblastoma.
Song M; Huang Y; Hong Y; Liu J; Zhu J; Lu S; Wang J; Sun F; Huang J; Xu J; Tang Y; Xia JC; Zhang Y
Oncoimmunology; 2024; 13(1):2289738. PubMed ID: 38125723
[TBL] [Abstract] [Full Text] [Related]
13. Neuroblastoma and Glioblastoma Cases With Amplified Oncogenes Have Reduced Numbers of tumor-Resident Adaptive Immune Receptor Recombinations.
Dabkowski TR; Varkhedi M; Song JJ; Gozlan EC; Blanck G
JCO Precis Oncol; 2023 Sep; 7():e2300057. PubMed ID: 38085056
[TBL] [Abstract] [Full Text] [Related]
14. The dual HDAC and PI3K inhibitor, CUDC‑907, inhibits tumor growth and stem‑like properties by suppressing PTX3 in neuroblastoma.
Li M; Hu Y; Wang J; Xu Y; Hong Y; Zhang L; Luo Q; Zhen Z; Lu S; Huang J; Zhu J; Zhang Y; Que Y; Sun F
Int J Oncol; 2024 Feb; 64(2):. PubMed ID: 38063204
[TBL] [Abstract] [Full Text] [Related]
15. Optimal combination of mycn differential gene and cellular senescence gene predicts adverse outcomes in patients with neuroblastoma.
Tan J; Wang C; Jin Y; Xia Y; Gong B; Zhao Q
Front Immunol; 2023; 14():1309138. PubMed ID: 38035110
[TBL] [Abstract] [Full Text] [Related]
16. Activating Transcription Factor 5 Promotes Neuroblastoma Metastasis by Inducing Anoikis Resistance.
Banerjee D; Boboila S; Okochi S; Angelastro JM; Kadenhe-Chiweshe AV; Lopez G; Califano A; Connolly EP; Greene LA; Yamashiro DJ
Cancer Res Commun; 2023 Dec; 3(12):2518-2530. PubMed ID: 38014922
[TBL] [Abstract] [Full Text] [Related]
17. Functional TET2 gene polymorphisms increase the risk of neuroblastoma in Chinese children.
Lin L; Wang B; Zhang X; Deng C; Zhou C; Zhu J; Wu H; He J
IUBMB Life; 2024 Apr; 76(4):200-211. PubMed ID: 38014648
[TBL] [Abstract] [Full Text] [Related]
18. The survivin-ran inhibitor LLP-3 decreases oxidative phosphorylation, glycolysis and growth of neuroblastoma cells.
Galiger C; Zohora FT; Dorneburg C; Tews D; Debatin KM; Beltinger C
BMC Cancer; 2023 Nov; 23(1):1148. PubMed ID: 38007466
[TBL] [Abstract] [Full Text] [Related]
19. Mitotic Dysregulation at tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for mycn-Driven Neuroblastoma.
Zhai L; Balachandran A; Larkin R; Seneviratne JA; Chung SA; Lalwani A; Tsubota S; Beck D; Kadomatsu K; Beckers A; Durink K; De Preter K; Speleman F; Haber M; Norris MD; Swarbrick A; Cheung BB; Marshall GM; Carter DR
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958555
[No Abstract] [Full Text] [Related]
20. Chromosome 1p36 candidate gene ZNF436 predicts the prognosis of neuroblastoma: a bioinformatic analysis.
Wang H; Wang X; Xu L
Ital J Pediatr; 2023 Oct; 49(1):145. PubMed ID: 37904225
[TBL] [Abstract] [Full Text] [Related]
[Next]
